micro-community-banner
  • Saved

2yr
Myasthenia Gravis as Initial Presentation of a Pancreatic Neuroendocrine Tumor: a Case Report

Myasthenia Gravis as Initial Presentation of a Pancreatic Neuroendocrine Tumor: a Case Report

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580239/

Myasthenia gravis (MG) is a heterogeneous autoimmune disease, which is characterized by a postsynaptic neuromuscular transmission defect.

Because the efficient treatment of neuroendocrine neoplasia (NEN) is instrumental in achieving a complete remission of myasthenia gravis, screening for rare neuroendocrine malignancies, including pancreatic NEN, could be considered in the diagnostic evaluation.

  • Saved

2yr
Coverage of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2023 Annual Meeting

The annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) brings together neurologists, physiatrists, researchers, and advanced practice providers to learn more about the latest advancements in neuromuscular disorders and musculoskeletal and electrodiagnostic medicine. The four-day meeting is taking place at the JW Marriott Phoenix Desert Ridge Resort & Spa.

Thanks to the advent of targeted therapies and improved diagnosis, myasthenia gravis, a chronic autoimmune neuromuscular disorder, took center stage during many presentations and symposia at this year’s meeting.

Click above for a summary of presentations that caught our eye at the conference.

  • Saved

2yr
Modifying Antibody-FcRn Interactions to Increase the Transport of Antibodies Through the Blood-Brain Barrier

Modifying Antibody-FcRn Interactions to Increase the Transport of Antibodies Through the Blood-Brain Barrier

Source : https://pubmed.ncbi.nlm.nih.gov/37381177/

The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders.

Several Fc mutations, such as certain substitutions found on efgartigimod, enhance antibody-FcRn interactions in low and high pH environments. The researchers propose that site-directed mutagenesis along the Fc-FcRn interface to search for mutations that enhance antibody-FcRn interactions in a pH-independent manner may identify substitutions...

  • Saved

2yr
Propofol TCI or Sevoflurane Anesthesia Without Muscle Relaxant for Thoracoscopic Thymectomy in Myasthenia Gravis Patients: a Prospective, Observational Study

Propofol TCI or Sevoflurane Anesthesia Without Muscle Relaxant for Thoracoscopic Thymectomy in Myasthenia Gravis Patients: a Prospective, Observational Study

Source : https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-023-02296-6

Myasthenia gravis (MG) patients interact unpredictably with anesthetic agents, including neuromuscular blocking agents. Here, we investigate the effectiveness of general anesthesia without muscle relaxants using either propofol via target-controlled infusion...

Anesthesia with propofol TCI or sevoflurane without muscle relaxants in patients with MG offered good intraoperative and postoperative conditions for thoracoscopic thymectomy.

  • Saved

2yr
Preview of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2023 Annual Meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) will host its annual meeting from Nov. 1 to 4, 2023, at the JW Marriott Desert Ridge in Phoenix.

Physicians, technologists, advanced practice providers, and other health care providers will gather to learn about the latest in neuromuscular, musculoskeletal, and electrodiagnostic medicine and neuromuscular ultrasound. 

We will be covering the event for you, so check your email for highlights and a wrap-up of the conference.

Click above for an exclusive preview of the event.